EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-SA 4.0

Efficacy and Safety of Tirzepatide in the Treatment of Obesity: A Review of Current Clinical Trials

Wojciech Kijowski, Knieszko Fahim, Jakub Franaszek, Nadia Herchi, Martyna Jabrzyk, Patrycja Jarczyńska, Mateusz Klusek, Karolina Michalak, Maciej Przybył

Quality in Sport · 05.04.2026 · 54 · 70307

DOI: 10.12775/qs.2026.54.70307 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Quality in Sport, online erschienen am 05.04.2026. Verfasst von Wojciech Kijowski und 8 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Obesity is a chronic disease with increasing prevalence and substantial health consequences. In recent years, advances in incretin-based pharmacotherapy have enabled greater weight loss than was achievable with earlier medications.

Aim

To evaluate the efficacy and safety of tirzepatide in the treatment of obesity based on current clinical trial evidence. Materials and methods: A narrative review of key randomized trials from the SURMOUNT program (including SURMOUNT-1 and SURMOUNT-4), longer-term follow-up data, and meta-analyses was performed. Outcomes included mean percent weight change, clinically relevant weight-loss thresholds, durability of effect after treatment withdrawal, and adverse events.

Results

In SURMOUNT-1, tirzepatide produced a significant, dose-dependent reduction in body weight, achieving a mean weight loss of up to approximately 21% at 72 weeks compared with placebo, and a substantial proportion of participants reached ≥20% weight loss at higher doses. In SURMOUNT-4, continued therapy was essential to maintain weight loss, whereas treatment discontinuation was associated with clinically meaningful weight regain. The most common adverse events were gastrointestinal (nausea, diarrhea, vomiting), typically mild to moderate in severity.

Conclusions

Tirzepatide is an effective pharmacological option for obesity with an acceptable safety profile; however, maintenance of benefits requires long-term treatment. Further studies are needed to clarify durability of effect and long-term safety over multiple years.

Zitieren

APA

Kijowski, W., Fahim, K., Franaszek, J., Herchi, N., Jabrzyk, M., Jarczyńska, P., Klusek, M., Michalak, K., & Przybył, M. (2026). Efficacy and Safety of Tirzepatide in the Treatment of Obesity: A Review of Current Clinical Trials. Quality in Sport, 54, 70307. https://doi.org/10.12775/qs.2026.54.70307

Vancouver

Kijowski W, Fahim K, Franaszek J, Herchi N, Jabrzyk M, Jarczyńska P, et al. Efficacy and Safety of Tirzepatide in the Treatment of Obesity: A Review of Current Clinical Trials. Quality in Sport. 2026;54:70307. doi:10.12775/qs.2026.54.70307

BibTeX
@article{Kijowski2026,
  author = {Kijowski, Wojciech and Fahim, Knieszko and Franaszek, Jakub and Herchi, Nadia and Jabrzyk, Martyna and Jarczyńska, Patrycja and Klusek, Mateusz and Michalak, Karolina and Przybył, Maciej},
  title = {Efficacy and Safety of Tirzepatide in the Treatment of Obesity: A Review of Current Clinical Trials},
  journal = {Quality in Sport},
  year = {2026},
  volume = {54},
  pages = {70307},
  doi = {10.12775/qs.2026.54.70307}
}
Kostenlos starten →